TMIGD2 and acute myeloid leukemia: In agreement with the in vitro data, knockdown of TMIGD2 resulted in significantly delayed human AML progression (Pt#5 and Pt#8), reduced engraftment potential (Pt#24 and Pt#26), and prolonged survival (Pt#5) in AML PDX models (Fig. 5f and Supplementary Fig. 5b, c), indicating that TMIGD2 is essential for the development of AML.